Impact of low estrogen- and progesterone-receptor expression on survival outcomes in breast cancers previously classified as triple-negative breast cancers.

Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival Outcomes

“…In our previous study, we found that 8 of 25 breast cancer patients had HER2-amplified tumors that changed to HER2-nonamplified after trastuzumab-based neoadjuvant therapy and that patients whose tumors remained HER2-positive had a longer RFS compared with patients whose tumors' HER2 status had changed. 13 In the present study, we found that among 35 patients who received trastuzumab, the 5-year RFS and 5-year OS estimates for patients whose tumors' HER2 status changed and patients whose tumors' HER2 status remained stable did not differ significantly (P ¼ .91 and .23, respectively). However, in our previous cohort, the proportion of HER2-positive tumors that changed to TNBC was greater than in the current study (75% vs. 48%).…”

“…Positive ER or PR status was defined as nuclear staining of ER or PR in 5% of tumor cells. 13 HER2 protein overexpression was defined as an IHC score of 3þ in 10% of tumor cells. If IHC score was 2þ, fluorescence in situ hybridization (FISH) was used.…”

HER2-positivity rates in breast cancer: no variation over time when clinicopathological features and testing are stable

“…Hormone receptor status was considered positive when either ER or PR status or both was positive (positive cutoff ≥10% of nuclear staining, according to French recommendations, Group for Evaluation of Prognostic Factors Using Immunohistochemistry in Breast Cancer 1999; and this cut-off is now supported by some molecular or clinical data, Ogawa et al 2004;Iwamoto et al 2012;Raghav et al 2012).…”

Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers

“…Their clinicopathologic features and event-free survival were between those of the Luminal A-like and the A higher rate of relapse in the new Luminal B-like subtype patients might be due to the PgR status, which is influenced by the efficacy of hormonal therapy. Previous analyses investigated whether the PgR status provided additional value to the ER status and improved the prediction of benefit from endocrine treatment among patients with primary breast cancer who received adjuvant endocrine therapy [13][14][15]. The authors concluded that PgRnegative patients benefit less from adjuvant endocrine therapy than PgR-positive patients and that they may want to consider chemotherapy [8,13].…”